SHENZHEN NEPTUNUS BIOENGINEERING CO., LTD.

Shenzhen Neptunus Bioengineering Co., Ltd.

000078

CNE000000X95

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 08/05/2024 BST			5-day change	1st Jan Change
2.53 ^CNY	+1.61%		+8.58%	-19.43%

04-29	Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-29	Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Shenzhen Neptunus Bioengineering Co., Ltd. Announces Executive Appointments

November 01, 2022 at 07:31 pm

Shenzhen Neptunus Bioengineering Co., Ltd. at its EGM held on 1 October 2022 appointed Zhang Simin, Zhang Yifei, Shen Dakai and Jin Rui as non-independent directors. Appointed Zhang Hua and Wang Huanjun as independent directors.

Latest news about Shenzhen Neptunus Bioengineering Co., Ltd.

Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Neptunus Bioengineering to Build Smart Logistics Park for 298 Million Yuan	04-25	MT
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	29/10/23	CI
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23	CI
UK Output Weakness Adds to BOE's Challenge	23/08/23	DJ
Shenzhen Neptunus Bioengineering to Set Up 150 Million Yuan Medical Equipment Unit	16/08/23	MT
FTSE 100 Closes Down 1.4% on US Credit Rating -2-	02/08/23	DJ
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Sector Update: Tech Stocks Edging Higher by Wednesday Close	15/03/23	MT
Sector Update: Tech	15/03/23	MT
FinVolution's Shares Fall Wednesday as Citigroup Downgrade Follows Lower Q4 Non-GAAP Earnings, Net Revenue	15/03/23	MT
FinVolution Group's Q4 Non-GAAP Earnings Decline, Revenue Rises; CEO Steps Down; Annual Dividend Raised	15/03/23	MT
Sterling May Fall Vs Euro as ECB More Aggressive -2-	07/03/23	DJ
Shenzhen Neptunus Bioengineering Warns of Loss in 2022	01/02/23	MT
Sterling Could Turn Lower Vs Dollar After Recent Gains	23/01/23	DJ
Shenzhen Neptunus Bioengineering Co., Ltd. Announces Executive Appointments	01/11/22	CI
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22	CI
FTSE 100 Closed Up Amid Falling Gas Prices, US Inflation Hopes	12/09/22	DJ
FTSE 100 Rises as Traders Eye Key US Inflation Data	12/09/22	DJ
Bets Against Pound Rise Amid Fears Over UK Growth, Fiscal Policy	12/09/22	DJ
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	24/08/22	CI
Hongta Securities Chairman, Two Others Resign as H1 Profit Halves	26/07/22	MT
Sterling to Be Little Affected by UK Leadership Debate	25/07/22	DJ
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/04/22	CI

Chart Shenzhen Neptunus Bioengineering Co., Ltd.

Duration

Period

Chart Shenzhen Neptunus Bioengineering Co., Ltd.

More charts

Company Profile

Shenzhen Neptunus Bioengineering Co.,Ltd is a China-based company principally engaged in pharmaceutical and food manufacturing and pharmaceutical commercial distribution businesses. The Companyâs main products include anti-tumor products, cardiovascular drugs, marine drugs, respiratory drugs, anti-infective products and other pharmaceuticals, as well as healthcare products, health food and medical instrument. The Company distributes its products mainly in domestic market, with East China as its main market.

Sector

Pharmaceuticals

Calendar

13/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
SHENZHEN NEPTUNUS BIOENGINEERING CO., LTD.	-19.43%	964M
CARDINAL HEALTH, INC.	-2.72%	23.88B
SINOPHARM GROUP CO. LTD.	+4.16%	8.29B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+8.61%	8.35B
HUADONG MEDICINE CO., LTD	-18.57%	8.18B
H. LUNDBECK A/S	+5.56%	4.81B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+19.12%	4.4B
EBOS GROUP LIMITED	-3.24%	4B
GALENICA AG	-1.86%	3.92B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+26.66%	3.79B

Pharmaceuticals Wholesale